It's never easy trying to convince the commercial side of a biopharmaceutical business why a company should go down the path of pursuing a product that may have great value in saving lives and preventing the spread of disease, but in the end, may not garner big profits.
That's what Jon Heinrichs, an associate vice president and segment head in global project leadership at Sanofi Pasteur's Swiftwater,...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
